Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Passes Above 200-Day Moving Average – Should You Sell?

Posted by Geri Gentry on Aug 5th, 2026

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $48.48 and traded as high as $55.01. Global X Genomics & Biotechnology ETF shares last traded at $54.89, with a volume of 41,980 shares changing hands.

Global X Genomics & Biotechnology ETF Stock Performance

The company has a market capitalization of $81.80 million, a PE ratio of -23.94 and a beta of 1.17. The firm’s 50-day simple moving average is $53.39 and its 200 day simple moving average is $48.53.

Global X Genomics & Biotechnology ETF Dividend Announcement

The business also recently disclosed a dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 29th were issued a dividend of $0.0579 per share. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s payout ratio is currently -27.35%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC increased its holdings in Global X Genomics & Biotechnology ETF by 30.9% in the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after buying an additional 4,615 shares in the last quarter. Sei Investments Co. grew its holdings in shares of Global X Genomics & Biotechnology ETF by 110.4% in the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after acquiring an additional 12,105 shares during the period. Wealth Management Partners LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the 1st quarter worth approximately $244,000. Creative Financial Designs Inc. ADV increased its stake in Global X Genomics & Biotechnology ETF by 4.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after purchasing an additional 481 shares in the last quarter. Finally, U.S. Capital Wealth Advisors LLC purchased a new position in Global X Genomics & Biotechnology ETF in the 4th quarter valued at approximately $575,000. 56.95% of the stock is currently owned by institutional investors and hedge funds.

About Global X Genomics & Biotechnology ETF

(Get Free Report)

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.